Review of “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”


One-Minute Summary

- This study examines the antibody (Ab) response in coronavirus disease 2019 (COVID-19) cases and investigates the use of serology for clinical testing.
- 2-5 serial samples were collected from 173 COVID-19 cases (N=535) from a single hospital in Shenzhen, China (Guangdong province) and tested for total Ab, IgM, and IgG.
- Seroconversion was 161/173 (93.1%) for total Ab, 143/173 (82.7%) for IgM, and 112/173 (64.7%) for IgG by 39 days post symptom onset.
- Median time from symptom onset to seroconversion was 11 days for total Ab, 12 days for IgM and 14 days for IgG. Total Ab and IgM positivity was ~100% by 1 month.
- Within the first week of illness, RNA detection was more sensitive compared to Ab detection (66.7% vs 19.1-38.3%); however, after 7 days, sensitivity of RNA gradually decreased (54.0% at 8-14 days, 45.5% at 15-39 days) while the sensitivities of Abs increased (100% for total Ab, 94.3% IgM, 79.8% IgG by day 15-39).
- Combining RNA and Ab detection increased sensitivity, most notably for RNA-negative cases in the late stages of illness.
- In longitudinal analyses of 9 patients, RNA was generally detected earlier (day 2-7) than Ab (day 1-19) and a rise in Abs was not always associated with viral RNA clearance.
- Total Ab titres were significantly higher in critically ill patients after 12 days of illness and were an independent predictor of severity.
- The authors conclude that Ab testing can be used as a supplement to RNA detection and as a marker for clinical severity in the later course of illness.

Additional Information

- COVID-19 cases were confirmed using real-time PCR on throat and nasal swabs. Cases included patients admitted to hospital between January 11 and February 9, 2020.
- Demographic and clinical characteristics of patients:
  - Median age: 48 years (interquartile range [IQR]: 35-61)
  - Female: 89/173 (51.4%)
  - Comorbidities: 41/173 (23.7%)
  - Severity: 32/173 (18.5%) were critically ill
- Outcome (as of Feb 19, 2020): 109/183 (63.0%) hospitalized; 62/173 (35.8%) recovered; 2/173 (1.2%) deceased
- Ab testing was done using a commercial enzyme-linked immunosorbent assays (ELISAs). The total Ab and IgM ELISAs used recombinant receptor binding domain (RBD) of the spike protein of COVID-19 as the antigen and the IgG ELISA used recombinant nucleoprotein as antigen. Using samples collected from healthy individuals before the emergence of COVID-19, specificity was determined to be 99.1% (211/213), 98.6% (210/213) and 99.0% (195/197) for total Ab, IgM, and IgG, respectively. Cross-reactivity with other coronaviruses was not assessed.
- Seroconversion was not detected in 12 patients but the authors state that this is likely due to early sample collection.
- Total Ab was detected in 17/35 (48.6%) of RNA-negative patients in ≤7 days of illness and in 86/87 (98.9%) in RNA-negative patients tested between 8-39 days of illness.
- Specimens past day 39 of illness were not tested; therefore, the duration of Abs is unknown.
- PCR sensitivity may have been higher if lower respiratory tract specimens were also tested.

**PHO Reviewer’s Comments**
- The performance characteristics for the commercial ELISAs were not provided.

**Citation**

**Disclaimer**
This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

**Public Health Ontario**
Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit [publichealthontario.ca](http://publichealthontario.ca)